1-7-22-W221 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan
Reconstitution of epigenetic nucleosomes
Histone H4 protein with designed acetylation, synthesized by combination of our genetic code expansion- and cell-free protein synthesis technologies. Pinpoint introduction of acetyllysines at designed sites was confirmed by mass spectrometry. Through this technology, we are now able to reconstitute an "epi-nucleosome" as schematically shown to the right.
Understanding of an epigenetic mechanism
Tertiary structure analysis of the BRD2 protein that is implicated in the onsets of carcinomas and atherosclerosis.
(Left) Structural mechanism how BRD2 protein recognizes one of transcriptionally-active chromatin marks (i.e. acetylation of Lys12 of histone H4).
(Right) Development of a BRD2-inhibiting compound, BIC1, based on the tertiary structure analysis.
Regulation of epigenetics
Histone demethylase inhibitor S2101, developed by our structure-based approaches. This compound is commercially available and is utilized as one of epigenetics-regulating reagents.